-- Quest Diagnostics (DGX) said Thursday that City of Hope is evaluating the Haystack MRD circulating tumor DNA test in a research program to help improve disease management for patients with solid tumor cancers.
The company said 14 City of Hope sites across the US are participating in the study, which is expected to enroll around 500 patients with breast, colorectal, ovarian, and prostate cancers.
The program will evaluate Haystack MRD in detecting minimal residual disease, monitoring treatment response, and identifying recurrence ahead of standard imaging under neoadjuvant, adjuvant, and post-treatment settings, Quest Diagnostics said.
Shares of Quest Diagnostics were up 1% in Thursday trading.
Price: $193.42, Change: $+2.00, Percent Change: +1.04%